P3.04-14 TMB and Immune Checkpoint Inhibitor Gene Expression Are Unrelated in NSCLC Patients

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1721
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P3.04-20 Correlation of Immune-Related Adverse Events and Response From Immune Checkpoint Inhibitors in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.04-15 IDO and Tim3 Gene Expression Is Correlated in NSCLC Patients With Low PDL1 Gene Expression

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.04-16 a Seven-Gene Expression Signature Reveals Unique Immune-Phenotypes Related to Major Oncogenic-Drivers in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.04-08 Identifying Resistance to Immune Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in PTS With NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Looking for the Best Immune-Checkpoint Inhibitor in Pre-Treated NSCLC Patients: An Indirect Comparison Between Nivolumab, Pembrolizumab and Atezolizumab

International Journal of Cancer
Cancer ResearchOncology
2017English

P3.04-18 the Efficacy and Safety of Solid Tumors Combination Therapy With Immune Checkpoint Inhibitor: A Systematic Review and Meta-Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Immune Checkpoint Inhibitor-Induced Fanconi Syndrome

Cureus
2020English

Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020

Kidney360
2020English

High TMB Predicts Immunotherapy Benefit in NSCLC

Cancer Discovery
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy